Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Phathom Pharmaceuticals (NASDAQ: PHAT) has announced it will host a live webcast on Thursday, March 6, 2025, at 8:30 am ET to present its fourth quarter and full year 2024 financial results along with a business update.
The company specializes in developing and commercializing treatments for gastrointestinal diseases. Their key product is vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) marketed in the US as VOQUEZNA®. The treatment is approved for heartburn associated with Non-Erosive GERD in adults, healing and maintenance of Erosive GERD, and comes in TRIPLE PAK® and DUAL PAK® combinations for H. pylori infection treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT) ha annunciato che ospiterà un webcast dal vivo giovedì 6 marzo 2025, alle 8:30 ET per presentare i risultati finanziari del quarto trimestre e dell'intero anno 2024, insieme a un aggiornamento aziendale.
L'azienda si specializza nello sviluppo e nella commercializzazione di trattamenti per malattie gastrointestinali. Il loro prodotto principale è vonoprazan, un inibitore della pompa protonica (PCAB) di prima classe commercializzato negli Stati Uniti come VOQUEZNA®. Il trattamento è approvato per il bruciore di stomaco associato a GERD non erosiva negli adulti, per la guarigione e il mantenimento della GERD erosiva, e viene fornito in combinazioni TRIPLE PAK® e DUAL PAK® per il trattamento dell'infezione da H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT) ha anunciado que llevará a cabo una transmisión web en vivo el jueves 6 de marzo de 2025, a las 8:30 am ET para presentar sus resultados financieros del cuarto trimestre y del año completo 2024, junto con una actualización comercial.
La empresa se especializa en el desarrollo y comercialización de tratamientos para enfermedades gastrointestinales. Su producto clave es vonoprazan, un bloqueador de ácido competitivo de potasio (PCAB) de primera clase comercializado en EE. UU. como VOQUEZNA®. El tratamiento está aprobado para la acidez estomacal asociada con GERD no erosiva en adultos, la curación y el mantenimiento de GERD erosiva, y se presenta en combinaciones TRIPLE PAK® y DUAL PAK® para el tratamiento de la infección por H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT)는 2025년 3월 6일 목요일 오전 8:30 ET에 2024년 4분기 및 연간 재무 결과와 사업 업데이트를 발표하기 위한 라이브 웹캐스트를 개최한다고 발표했습니다.
이 회사는 위장 질환 치료제를 개발하고 상용화하는 데 전문화되어 있습니다. 그들의 주요 제품은 vonoprazan으로, 미국에서 VOQUEZNA®로 판매되는 최초의 칼륨 경쟁 산 차단제(PCAB)입니다. 이 치료는 성인의 비침식성 GERD와 관련된 속쓰림, 침식성 GERD의 치유 및 유지에 대해 승인되었으며, H. pylori 감염 치료를 위한 TRIPLE PAK® 및 DUAL PAK® 조합으로 제공됩니다.
Phathom Pharmaceuticals (NASDAQ: PHAT) a annoncé qu'elle organisera un webinaire en direct le jeudi 6 mars 2025 à 8h30 ET pour présenter ses résultats financiers du quatrième trimestre et de l'année complète 2024, ainsi qu'une mise à jour de l'entreprise.
L'entreprise est spécialisée dans le développement et la commercialisation de traitements pour les maladies gastro-intestinales. Leur produit phare est vonoprazan, un bloqueur d'acide compétitif au potassium (PCAB) de première classe commercialisé aux États-Unis sous le nom de VOQUEZNA®. Ce traitement est approuvé pour les brûlures d'estomac associées à la GERD non érosive chez les adultes, pour la guérison et le maintien de la GERD érosive, et se présente en combinaisons TRIPLE PAK® et DUAL PAK® pour le traitement de l'infection à H. pylori.
Phathom Pharmaceuticals (NASDAQ: PHAT) hat angekündigt, dass am Donnerstag, den 6. März 2025, um 8:30 Uhr ET ein Live-Webcast stattfinden wird, um die Finanzzahlen des vierten Quartals und des gesamten Jahres 2024 sowie ein Unternehmensupdate zu präsentieren.
Das Unternehmen ist auf die Entwicklung und Vermarktung von Behandlungen für gastrointestinale Erkrankungen spezialisiert. Ihr Hauptprodukt ist vonoprazan, ein erstklassiger kaliumkompetitiver Säureblocker (PCAB), der in den USA unter dem Namen VOQUEZNA® vermarktet wird. Die Behandlung ist für Sodbrennen im Zusammenhang mit nicht erosiver GERD bei Erwachsenen, die Heilung und Erhaltung von erosiver GERD zugelassen und wird in Kombinationen von TRIPLE PAK® und DUAL PAK® zur Behandlung von H. pylori-Infektionen angeboten.
- None.
- None.
- Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET
FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 6, 2025, to report its fourth quarter and full year 2024 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
When will Phathom Pharmaceuticals (PHAT) report Q4 and FY 2024 earnings?
What treatments does Phathom Pharmaceuticals (PHAT) currently market in the US?
How can investors access Phathom Pharmaceuticals' (PHAT) Q4 2024 earnings webcast?
What are the approved indications for VOQUEZNA by Phathom Pharmaceuticals (PHAT)?
